
Keros Therapeutics Inc is a biotechnology business based in the US. Keros Therapeutics Inc shares (KROS) are listed on the NASDAQ and all prices are listed in US Dollars. Keros Therapeutics Inc employs 75 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Keros Therapeutics Inc
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – KROS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Keros Therapeutics Inc stock price (NASDAQ: KROS)
Use our graph to track the performance of KROS stocks over time.Keros Therapeutics Inc shares at a glance
Latest market close | $26.03 |
---|---|
52-week range | $24.38 - $68.29 |
50-day moving average | $42.06 |
200-day moving average | $47.63 |
Wall St. target price | $93.75 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.85 |
Buy Keros Therapeutics Inc shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Keros Therapeutics Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Keros Therapeutics Inc price performance over time
Historical closes compared with the close of $26.03 from 2022-06-28
1 week (2022-06-22) | -1.55% |
---|---|
1 month (2022-05-27) | -25.95% |
3 months (2022-03-30) | -51.49% |
6 months (2021-12-30) | -53.77% |
1 year (2021-06-30) | -38.71% |
---|---|
2 years (2020-06-30) | -30.61% |
3 years (2019-06-26) | N/A |
5 years (2017-06-26) | N/A |
Keros Therapeutics Inc financials
Revenue TTM | $20.1 million |
---|---|
Gross profit TTM | $-35,043,000 |
Return on assets TTM | -16.42% |
Return on equity TTM | -28.42% |
Profit margin | 0% |
Book value | $9.31 |
Market capitalisation | $686.4 million |
TTM: trailing 12 months
Keros Therapeutics Inc share dividends
We're not expecting Keros Therapeutics Inc to pay a dividend over the next 12 months.
Keros Therapeutics Inc share price volatility
Over the last 12 months, Keros Therapeutics Inc's shares have ranged in value from as little as $24.38 up to $68.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Keros Therapeutics Inc's is 1.2249. This would suggest that Keros Therapeutics Inc's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Keros Therapeutics Inc overview
Keros Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. .
Keros Therapeutics Inc in the news
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association
Frequently asked questions
What percentage of Keros Therapeutics Inc is owned by insiders or institutions?Currently 11.457% of Keros Therapeutics Inc shares are held by insiders and 89.383% by institutions. How many people work for Keros Therapeutics Inc?
Latest data suggests 75 work at Keros Therapeutics Inc. When does the fiscal year end for Keros Therapeutics Inc?
Keros Therapeutics Inc's fiscal year ends in December. Where is Keros Therapeutics Inc based?
Keros Therapeutics Inc's address is: 99 Hayden Avenue, Lexington, MA, United States, 02421 What is Keros Therapeutics Inc's ISIN number?
Keros Therapeutics Inc's international securities identification number is: US4923271013 What is Keros Therapeutics Inc's CUSIP number?
Keros Therapeutics Inc's Committee on Uniform Securities Identification Procedures number is: 492327101
More guides on Finder
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
-
How to buy NYIAX (NYX) stock when it goes public
Everything we know about the NYIAX IPO, plus information on how to buy in.
-
How to buy Adamas One Corp (JEWL) stock when it goes public
Everything we know about the Adamas One Corp IPO, plus information on how to buy in.
-
How to buy Glucose Health (GLUC) stock when it goes public
Everything we know about the Glucose Health IPO, plus information on how to buy in.
-
How to buy Boustead Wavefront (BOUW) stock when it goes public
Everything we know about the Boustead Wavefront IPO, plus information on how to buy in.
-
How to buy ParaZero Technologies (PRZO) stock when it goes public
Everything we know about the ParaZero Technologies IPO, plus information on how to buy in.
Ask an Expert